OxFORD Asset Management LLP boosted its stake in Amarin Corporation PLC (NASDAQ:AMRN) by 114.2% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 135,773 shares of the biopharmaceutical company’s stock after acquiring an additional 72,390 shares during the quarter. OxFORD Asset Management LLP owned 0.05% of Amarin Corporation PLC worth $547,000 as of its most recent filing with the SEC.
A number of other institutional investors also recently added to or reduced their stakes in the stock. Wells Fargo & Company MN boosted its stake in Amarin Corporation PLC by 4.8% during the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 1,500 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in Amarin Corporation PLC by 27.1% during the 1st quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 7,580 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in Amarin Corporation PLC by 20.3% during the 2nd quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock worth $167,000 after purchasing an additional 7,000 shares during the last quarter. Airain ltd boosted its position in shares of Amarin Corporation PLC by 382.9% during the 2nd quarter. Airain ltd now owns 87,122 shares of the biopharmaceutical company’s stock valued at $351,000 after acquiring an additional 69,081 shares during the last quarter. Finally, Point72 Asset Management L.P. acquired a new position in shares of Amarin Corporation PLC during the 1st quarter valued at about $960,000. 37.76% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: This piece was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another website, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/10/28/amarin-corporation-plc-amrn-position-boosted-by-oxford-asset-management-llp.html.
In other Amarin Corporation PLC news, insider Steven B. Ketchum sold 63,479 shares of the stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $3.48, for a total value of $220,906.92. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 3.72% of the stock is currently owned by company insiders.
Amarin Corporation PLC (NASDAQ:AMRN) opened at 3.33 on Friday. The stock’s 50 day moving average price is $3.35 and its 200-day moving average price is $3.34. The firm’s market capitalization is $901.74 million. Amarin Corporation PLC has a 12 month low of $2.75 and a 12 month high of $4.47.
Amarin Corporation PLC (NASDAQ:AMRN) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $44.95 million for the quarter, compared to the consensus estimate of $40.35 million. The firm’s revenue was up 37.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.07) earnings per share. On average, analysts forecast that Amarin Corporation PLC will post ($0.21) earnings per share for the current year.
Several research analysts have recently weighed in on AMRN shares. BidaskClub cut shares of Amarin Corporation PLC from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 24th. Zacks Investment Research lowered shares of Amarin Corporation PLC from a “buy” rating to a “hold” rating in a report on Monday, August 7th. HC Wainwright restated a “buy” rating and issued a $10.00 price objective on shares of Amarin Corporation PLC in a report on Wednesday, August 9th. ValuEngine upgraded shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a report on Thursday, August 31st. Finally, Jefferies Group LLC boosted their price objective on shares of Amarin Corporation PLC from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, June 30th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $7.75.
Amarin Corporation PLC Company Profile
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.